KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Total Current Liabilities: 2009-2024

Historic Total Current Liabilities for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $607.0 million.

  • Biomarin Pharmaceutical's Total Current Liabilities rose 11.57% to $798.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $798.4 million, marking a year-over-year increase of 11.57%. This contributed to the annual value of $607.0 million for FY2024, which is 48.43% down from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Total Current Liabilities stood at $607.0 million for FY2024, which was down 48.43% from $1.2 billion recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Total Current Liabilities registered a high of $1.2 billion during FY2023, and its lowest value of $492.5 million during FY2020.
  • For the 3-year period, Biomarin Pharmaceutical's Total Current Liabilities averaged around $791.0 million, with its median value being $607.0 million (2024).
  • In the last 5 years, Biomarin Pharmaceutical's Total Current Liabilities spiked by 99.87% in 2023 and then slumped by 48.43% in 2024.
  • Biomarin Pharmaceutical's Total Current Liabilities (Yearly) stood at $492.5 million in 2020, then increased by 10.95% to $546.5 million in 2021, then increased by 7.76% to $588.9 million in 2022, then surged by 99.87% to $1.2 billion in 2023, then plummeted by 48.43% to $607.0 million in 2024.